Seattle Genetics to Present at BIO CEO & Investor Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the Biotechnology Industry Organization (BIO) CEO & Investor Conference on Wednesday, February 13, 2008, at 11:45 a.m. Eastern Time. The conference is being held at the Waldorf-Astoria Hotel in New York City.

A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the “news and investor information” section.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company has a worldwide collaboration with Genentech to develop and commercialize SGN-40. Seattle Genetics also has two other lead clinical product candidates in ongoing clinical trials: SGN-33 and SGN-35. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys.